Testoluten

Testoluten is a Khavinson-class peptide bioregulator derived from testicular tissue, developed as part of Vladimir Khavinson's systematic organ-specific bioregulator research program at the St. Petersburg Institute of Bioregulation and Gerontology, and proposed to restore gene expression and functional parameters in aging testicular tissue through peptide-chromatin regulatory element interaction rather than hormonal receptor agonism. As a testicular tissue-derived bioregulator, Testoluten is positioned within the Khavinson framework as a compound designed to modulate transcription in Leydig cells and Sertoli cells, potentially influencing testosterone biosynthesis, spermatogenesis, and testicular aging by reactivating gene expression programs that decline with age and environmental stress. Published research on the Khavinson peptide bioregulator class documents the systematic characterization of organ-specific short peptides and their proposed epigenetic mechanisms, with class-level evidence from animal models and human observational studies supporting the concept of peptide-mediated restoration of tissue-specific physiological parameters. Testoluten has no FDA approval and no approved indication in any Western jurisdiction; no indexed PubMed publications specifically report clinical outcomes for testoluten in controlled human studies, and the compound is available only through the Russian bioregulator market under the class-level evidence framework published by the Khavinson group.